Erratum to: No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers

被引：0
|
作者：
Nianhang Chen
Daniel Weiss
Josephine Reyes
Liangang Liu
Claudia Kasserra
Xiaomin Wang
Simon Zhou
Gondi Kumar
Lilia Weiss
Maria Palmisano
机构：
[1] Celgene Corporation,
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：659 / 660
页数：1
相关论文
共 8 条
  • [1] No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
    Chen, Nianhang
    Weiss, Daniel
    Reyes, Josephine
    Liu, Liangang
    Kasserra, Claudia
    Wang, Xiaomin
    Zhou, Simon
    Kumar, Gondi
    Weiss, Lilia
    Palmisano, Maria
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 1031 - 1039
  • [2] No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers
    Nianhang. Chen
    Daniel Weiss
    Josephine Reyes
    Liangang Liu
    Claudia Kasserra
    Xiaomin Wang
    Simon Zhou
    Gondi Kumar
    Lilia Weiss
    Maria Palmisano
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1031 - 1039
  • [3] No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers (vol 73, pg 1031, 2014)
    Chen, Nianhang
    Weiss, Daniel
    Reyes, Josephine
    Liu, Liangang
    Kasserra, Claudia
    Wang, Xiaomin
    Zhou, Simon
    Kumar, Gondi
    Weiss, Lilia
    Palmisano, Maria
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 659 - 660
  • [4] Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus
    Chen, Nianhang
    Weiss, Daniel
    Reyes, Josephine
    Liu, Liangang
    Kasserra, Claudia
    Wang, Xiaomin
    Zhou, Simon
    Kumar, Gondi
    Weiss, Lilia
    Palmisano, Maria
    BLOOD, 2013, 122 (21)
  • [5] Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies
    Martin, Paul
    Gillen, Michael
    Millson, David
    Oliver, Stuart
    Brealey, Clive
    Elsby, Robert
    Baluom, Muhammad
    Lau, David
    Mant, Tim
    CLINICAL THERAPEUTICS, 2015, 37 (12) : 2811 - 2822
  • [6] Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies.
    Zurth, Christian
    Graudenz, Kristina
    Denner, Karsten
    Korjamo, Timo
    Fricke, Robert
    Wilkinson, Gary
    Seitz, Friedeborg
    Prien, Olaf
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] DRUG-DRUG INTERACTIONS BETWEEN CENOBAMATE AND OTHER ANTIEPILEPTIC DRUGS: RESULTS FROM PHASE I STUDIES WITH CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, AND DIVALPROEX SODIUM.
    Vernillet, L.
    Kamin, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S91 - S91
  • [8] Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study
    Desch, Michael
    Schlecker, Christina
    Hohl, Kathrin
    Liesenfeld, Karl-Heinz
    Chan, Tom
    Mueller, Fabian
    Wunderlich, Glen
    Keller, Sascha
    Ishiguro, Naoki
    Wind, Sven
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2023, 43 (02) : 113 - 121
1